Imara, a clinical-stage biopharmaceutical company focused on sickle cell disease (SCD) and other hemoglobinopathies, announced the closing of an oversubscribed $63 million Series B cross-over financing.
Merck KGaA, Darmstadt, Germany, is collaborating with Iktos, a French start-up company specialized in artificial intelligence (AI) for new drug design, to further accelerate its drug discovery capabilities.
US-based Seres Therapeutics and AstraZeneca have entered into a three-year research collaboration, which will focus on further understanding the potential of microbiome therapeutics in supplementing immuno-oncology treatment.
InventisBio Inc., a clinical stage biotech company, announced the closing of a $70 million USD Series C financing in January 2019.
TaiwanJ Pharmaceuticals has signed a $26 million contract with Newsoara Biopharma to license out its drug candidate JKB-122 for further development in Asia.
Biopharmaceutical firm GTx has entered into a merger agreement with clinical-stage biotechnology firm Oncternal Therapeutics to create a new a publicly-traded and clinical-stage oncology company.
Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, announced the successful completion of a $135m Series B financing.
GeoVax Labs, a biotechnology company developing human vaccines, has expanded its collaboration activities with Leidos, to develop malaria vaccine candidates.
American multinational biotechnology company Biogen has agreed to acquire UK-based clinical-stage gene therapy firm Nightstar Therapeutics in a deal valued at around $877m.
Abpro, a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases, and NJCTTQ, a global pharmaceutical company, have entered into an agreement to develop multiple novel bispecific antibody therapies in immuno-oncology, including best-in -class T-cell engagers.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.